Get the Daily Brief
Latest Biotech News
Continuous Biologics Manufacturing: Industry Shift to Cost-Efficiency
Biopharmaceutical manufacturers are increasingly adopting continuous manufacturing techniques over traditional fed-batch methods for monoclonal antibody (mAb) production. Studies demonstrate...
ProKidney's Mixed Phase II Results Boost Kidney Disease Therapy Hope
ProKidney Corp. reported mixed data from its Phase II REGEN-007 trial evaluating rilparencel, a cell therapy for chronic kidney disease (CKD) in diabetic patients. In the two-dose cohort,...
Arvinas CEO John Houston to Retire Amid Protein Degrader Program Progress
Arvinas announced CEO John Houston will retire after over eight years steering the company, as its lead PROTAC (proteolysis-targeting chimera) protein degrader program nears a critical development...
Actithera Secures $75.5M Series A To Develop FAP-Targeted Radiopharmaceuticals
Radiopharmaceutical developer Actithera closed a $75.5 million Series A financing round to advance clinical development of small-molecule therapeutics targeting fibroblast activation protein...
FDA Approvals Target Alzheimer’s and Non-Small Cell Lung Cancer Updates
The FDA granted approval for a modified dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla to reduce risk of brain swelling, aiming to increase physician adoption. Meanwhile, Dizal...
Biopharma Layoffs Surge 32% in First Half 2025 Amid Industry Challenges
The biopharma sector experienced a sharp rise in workforce reductions during the first half of 2025, with 128 reported layoff rounds—32% more than the same period last year. Multiple companies...
New AI Collaborations Accelerate Oncology Drug Discovery
Iambic Therapeutics and Revolution Medicines entered a multi-year partnership integrating Iambic's AI-driven NeuralPLexer platform with Revolution’s proprietary oncology data. The collaboration...
Merck’s $10 Billion Bet on Verona Pharma’s Lung Drug
Merck & Co. has agreed to acquire London-based Verona Pharma for $10 billion, securing the rights to Ohtuvayre, a lung drug recently approved by the FDA for chronic obstructive pulmonary disease...
FDA Approves New Dosing and Tests for Alzheimer’s and Colorectal Cancer
The FDA granted approval for Eli Lilly’s revised dosing regimen of Alzheimer’s drug Kisunla to reduce the risk of brain swelling, addressing safety concerns that had limited its adoption....
ProKidney’s Kidney Disease Cell Therapy Shows Mixed Phase II Results
ProKidney Corp. reported encouraging Phase II trial results for its cell therapy rilparencel in chronic kidney disease patients, showing a 78% slowing of kidney function decline in the two-dose...
AI and Computational Tools Accelerate Cancer Drug Discovery and Protein Engineering
Partnerships and technology developments are advancing AI-driven drug discovery and protein engineering. Revolution Medicines and Iambic Therapeutics formed a multi-year collaboration leveraging...
Biopharma Industry Faces Rising Layoffs and Funding Challenges
Layoffs in the biopharma sector surged 32% year-over-year in the first half of 2025, marking an all-time high for monthly reduction-in-force rounds, with 29 reported in May alone. Several biotechs...
Innovations in Gene Editing and RNA Therapeutics
Gene editing techniques and RNA-based therapeutic platforms continue to evolve, expanding treatment potential. A CRISPR-based in vivo genome editing approach enabled mice to produce their own...
Advances in Rare Disease Therapies and Gene Therapy Trials
Novel treatments for rare diseases and gene therapies reported progress. Solid Biosciences received FDA and Health Canada clearance to begin Phase I trials for SGT-501 gene therapy targeting...
Novel Enzymes and Microbial Mechanisms Target Environmental and Biotech Applications
Scientists have uncovered enzymes and microbial functions with implications for environmental sustainability and biotechnology. Researchers at Leiden identified a common enzyme aiding bacterial...
Drug Industry Faces Regulatory, Pricing, and Legal Challenges
The pharmaceutical industry is grappling with regulatory and market complexities. Lawsuits accusing generic drugmakers of price fixing have escalated, with Southwest Airlines filing suit for...
Significant Biopharma Collaborations and Strategic Expansions
Biotech and pharmaceutical companies have entered several strategic partnerships and expansion initiatives. HeartBeat Bio and BiotxAI formed a collaboration to discover and validate genomic...
Merck’s $10B Push Into Lung Disease via Verona Pharma Buy
Merck announced a $10 billion acquisition of Verona Pharma to enhance its respiratory disease portfolio, focusing on chronic obstructive pulmonary disease (COPD). The deal includes the recently...
KalVista Secures FDA Approval for Oral Hereditary Angioedema Drug Ekterly
KalVista Pharmaceuticals won FDA approval for Ekterly (sebetralstat), the first oral on-demand therapy for hereditary angioedema (HAE) attacks in patients aged 12 and older. The approval follows a...
ProKidney’s Cell Therapy Shows Promise Amid Mixed Clinical Trial Results
ProKidney’s rilparencel, a cell therapy for chronic kidney disease (CKD), presented mixed findings in a phase 2 trial. One cohort receiving two injections demonstrated a significant 78% slowing in...